CEFIZOX by Astellas is clinical pharmacology the table below demonstrates the serum levels and duration of cefizox (ceftizoxime for injection, usp) following im administration of 500 mg and 1 gram doses, respectively, to normal volunteers. Approved for the treatment of infections due to susceptible strains of the microorganisms listed below. First approved in 1983.
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
CEFIZOX (ceftizoxime for injection, USP) is a third-generation cephalosporin antibiotic administered via intramuscular or intravenous injection. It treats susceptible bacterial infections across multiple body systems by inhibiting bacterial cell-wall synthesis and exhibits broad-spectrum activity against gram-positive, gram-negative, and anaerobic organisms. The drug achieves therapeutic concentrations in cerebrospinal fluid, bile, bone, and other tissues, making it suitable for serious systemic and localized infections.
Product is in late-stage lifecycle with approaching loss of exclusivity, signaling reduced commercial investment and team contraction.
Clinical Pharmacology The table below demonstrates the serum levels and duration of Cefizox (ceftizoxime for injection, USP) following IM administration of 500 mg and 1 gram doses, respectively, to normal volunteers. Serum Concentrations After Intramuscular Administration Serum Concentration…
Worked on CEFIZOX at Astellas? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on CEFIZOX offers limited career growth opportunity as the product approaches loss of exclusivity with zero linked job openings. Roles focus on defensive strategy, hospital contracting, and managed decline rather than innovation or expansion.